Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
14 June 2023

John Schaetzl will be greatly missed

We at the Access to Medicine Foundation are deeply saddened to announce the passing of John Schaetzl, who served as Chair of the Supervisory Board and supported the work of the Foundation over many years.

John brought his extensive private sector experience to bear on the issue of how to sustainably expand access to medicine in low- and middle-income countries. This included his decade with GE Asset Management, during which he managed global life-science investment funds – advising large foundations, government agencies and fund managers on investing that supports economic development and sustainable access-to-health outcomes. He was previously an executive at the pharmaceutical company Bayer. 

John will be remembered fondly by all who worked with him at the Access to Medicine Foundation, and by his fellow members of the Supervisory Board. Our thoughts and sympathies are with his friends and family. 

Since John joined the Supervisory Board in 2014, his insights, advice and guidance have been invaluable to both me and the Foundation. He was an amazing leader, perpetually full of positive energy, and always generous with both his time and knowledge. His loss is deeply felt.

Jayasree K. Iyer

Chief Executive Officer, Access to Medicine Foundation

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved